Objectives High-protein parenteral nutrition (PN) has been developed to counteract muscle loss in patients with cancer treated with PN. Nevertheless, it is not clear if high-protein PN is as safe as standard PN in patients with palliative cancer. Our primary aim was to compare the proportion of patients with elevated liver enzymes between…[Read more]

In this commentary, we welcome Schimmack’s reanalysis of Bar-Anan and Vianello’s multitrait multimethod (MTMM) data set, and we highlight some limitations of both the original and the secondary analyses. We note that when testing the fit of a confirmatory model to a data set, theoretical justifications for the choices of the measures to include in…[Read more]